htai 2015 - cost-effectiveness analysis of bevacizumab and cetuximab in advanced colorectal cancer...

17
v Clinical and economic evaluation of diaphragm pacing for ventilator- dependent patients: a Public Health System perspective University of Campinas Health Secretary of São Paulo State Heart Institute - University of São Paulo ADRIANA CAMARGO DE CARVALHO VIVIAN C. ANTUNES DOS SANTOS ERICA MIE OKUMURA SILVIA YUKARI TOGORO MIGUEL L. TEDDE EVELINDA TRINDADE ANDRÉ DEEKE SASSE

Upload: rebratsoficial

Post on 16-Aug-2015

100 views

Category:

Health & Medicine


0 download

TRANSCRIPT

Page 1: HTAi 2015 - Cost-effectiveness analysis of bevacizumab and cetuximab in advanced colorectal cancer II

v

Clinical and economic evaluation of diaphragm pacing for ventilator-dependent patients: a Public Health System perspective

University of CampinasHealth Secretary of São Paulo StateHeart Institute - University of São Paulo

ADRIANA CAMARGO DE CARVALHO VIVIAN C. ANTUNES DOS SANTOSERICA MIE OKUMURASILVIA YUKARI TOGORO

MIGUEL L. TEDDEEVELINDA TRINDADEANDRÉ DEEKE SASSE

Page 2: HTAi 2015 - Cost-effectiveness analysis of bevacizumab and cetuximab in advanced colorectal cancer II

Brazilian Public Health System

Health: right of the population and duty of the government

SUSUnified Health System

Universality

Integrality

Equality

Page 3: HTAi 2015 - Cost-effectiveness analysis of bevacizumab and cetuximab in advanced colorectal cancer II

THE PROBLEM

Higher incidence of complications

and discomfort for patients

High costs

Shortage of hospital beds

Elevate number of chronic patients in ICU only for ventilatory support

Page 4: HTAi 2015 - Cost-effectiveness analysis of bevacizumab and cetuximab in advanced colorectal cancer II

Surgical procedure to restoringbreathing through direct stimulation ofdiaphragm

Goal: Replace, delay or reduce theneed for mechanical ventilation

Main Indications: hight cervical spinalcord injury and other ventilatorydiseases

Page 5: HTAi 2015 - Cost-effectiveness analysis of bevacizumab and cetuximab in advanced colorectal cancer II

CURRENT CONTEXT

A single brand is registered by the Brazilian regulatory agency

Commercial monopoly

Disproportionately high costs

Elevate number of lawsuits

Costly to the public system

Few number of individuals benefited

OUR QUESTION: Is it viable to incorporate DP in the Brazillianpublic health system?

Page 6: HTAi 2015 - Cost-effectiveness analysis of bevacizumab and cetuximab in advanced colorectal cancer II

To quantify the added benefit when DP is used compared to the ventilator for patients with chronic respiratory failure

To evaluate the economic impact of DP use versus the use of mechanical ventilation from the Brazilian public health perspective

OBJECTIVES

Page 7: HTAi 2015 - Cost-effectiveness analysis of bevacizumab and cetuximab in advanced colorectal cancer II

SYSTEMATIC REVIEW

Clinical trials (randomized or non-randomized),

case series (prospective or retrospective),

HTA informs

Search Strategy updated up until November 2014

Two independent researchers

MEDLINE, EMBASE & Lilacs

Sensitive search strategy

Western idioms

• Population: In ventilator-dependent patients with chronic respiratory

failure...

• Intervention: ...does DP (thoracic or intradiaphragmatic)

• Comparator: ...compared to mechanical ventilation alone...

• Outcome: ... bring benefits in terms of weaning patients off of

mechanical ventilation and/or improve the quality of life?

PICO

Page 8: HTAi 2015 - Cost-effectiveness analysis of bevacizumab and cetuximab in advanced colorectal cancer II

Identified 72 articles usingPubMed, EMBASE and Lilacs

16 Full-text articles assessed for elegibility

56 citations removed: did notmeet inclusion criteria

(case reports)

11 studies included in review:

• 6 retrospective estudies• 5 prospective estudies

3 prospective non-randomized2 prospective randomized

5 full-text articles excluded:focus not of interest

and diverse study design

SYSTEMATIC REVIEW

Page 9: HTAi 2015 - Cost-effectiveness analysis of bevacizumab and cetuximab in advanced colorectal cancer II

EFFICACY CONCLUSIONS

Quality of data was low.Risks and benefits were difficult to characterise and quantify.

Possible positive effect on weaning patients from mechanical ventilation.

Potential improvement of quality of life level.

It can be considered safe

Phrenic nerve integrity must be proven by neuromuscular tests

The most established indications are for spinal cord injury and Congenital Central Hypoventilation

Page 10: HTAi 2015 - Cost-effectiveness analysis of bevacizumab and cetuximab in advanced colorectal cancer II

ECONOMIC ANALYSIS METHOD

ICUHome Care - MVHome Care – DP and MV

Three Different Scenarios

Design

Cost Analysis

Perspective

Brazillian Public Health System (SUS)

Cost – Data Sources

Real costs - Heart Institute - University of São Paulo (USP)Lawsuits - Health Secretary of São Paulo State

Page 11: HTAi 2015 - Cost-effectiveness analysis of bevacizumab and cetuximab in advanced colorectal cancer II

Costs - MV in Intensive Care Units

263

1,913

7,820

3,150

3,020

2,576

1,095

0 1000 2000 3000 4000 5000 6000 7000 8000 9000

Hemotherapy

Honoraria

Daily Cost

Diagnostic Tests

Supplies

Drugs

Appliances and Gases

Dollars (US$)

Monthly Average Costs

Total: ~20K (US$)

Page 12: HTAi 2015 - Cost-effectiveness analysis of bevacizumab and cetuximab in advanced colorectal cancer II

COSTS - Diaphragm Pacing System

129,3

25

53,87

0

20

40

60

80

100

120

140

Mark IV® (Avery) NeuRx DPS System®(Synapse Biomedical)

Atrostim PNS V2.0®(Atrotech)

Tho

usa

nd

Do

llars

(US$

)

Single brand registered by the Brazilian regulatory agency

Monopolar SystemQuadripolar

System

Page 13: HTAi 2015 - Cost-effectiveness analysis of bevacizumab and cetuximab in advanced colorectal cancer II

COSTS – Implantation of DP

318

2,530

450

328

103

0 500 1000 1500 2000 2500 3000

Multiprofessional Honoraria

Fees

Diagnostic Tests

Supplies

Drugs

Dollars (US$)

Surgery Average Costs

Total: 3,730K (US$)

Page 14: HTAi 2015 - Cost-effectiveness analysis of bevacizumab and cetuximab in advanced colorectal cancer II

MONTHLY HOME CARE COSTS

4,102

1,176992

495

1,235

3,572

1,176992

213 79

0

500

1.000

1.500

2.000

2.500

3.000

3.500

4.000

4.500

Human Resources EquipamentLeasing

Inputs Gas Therapy Services

MECHANICAL VENTILATION - Total: 8K

DIAPHRAGM PACING + MECHANICAL VENTILATION - Total: 6K

Page 15: HTAi 2015 - Cost-effectiveness analysis of bevacizumab and cetuximab in advanced colorectal cancer II

63,6

6 6 6 6 6 6

96,3

0

20

40

60

80

100

120

140

1 2 3 4 5 6 TOTAL

Tho

usa

nd

Do

llars

Months

DP – Home Care

Inicial Cost Monthly Cost Cost in 6 months

20 20 20 20 20 20

120

0

20

40

60

80

100

120

140

1 2 3 4 5 6 TOTAL

Tho

usa

nd

Do

llars

Months

MV-Intensive Care Unit

Monthly Cost Cost in 6 months

AVERAGE COSTS: Current Scenario vs DP Implantation

Page 16: HTAi 2015 - Cost-effectiveness analysis of bevacizumab and cetuximab in advanced colorectal cancer II

CONCLUSION – ECONOMIC ANALYSIS

The installation of the DP and the patient transfer to his residence would generate savings of financial resources

Breaking the current monopoly and promoting market opening would also probably reduce the costs of the technology

More appropriate economic models could be developed if there was more and better data on efficacy/effectiveness and quality of life

Page 17: HTAi 2015 - Cost-effectiveness analysis of bevacizumab and cetuximab in advanced colorectal cancer II

v

Thank youADRIANA CAMARGO DE [email protected]

ANDRÉ DEEKE SASSE [email protected]